U.S. Medical Eligibility Criteria for Contraceptive Use, 2024
Overview
Authors
Affiliations
The 2024 U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) comprises recommendations for the use of specific contraceptive methods by persons who have certain characteristics or medical conditions. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national experts in Atlanta, Georgia, during January 25-27, 2023. The information in this report replaces the 2016 U.S. MEC (CDC. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR 2016:65[No. RR-3]:1-103). Notable updates include 1) the addition of recommendations for persons with chronic kidney disease; 2) revisions to the recommendations for persons with certain characteristics or medical conditions (i.e., breastfeeding, postpartum, postabortion, obesity, surgery, deep venous thrombosis or pulmonary embolism with or without anticoagulant therapy, thrombophilia, superficial venous thrombosis, valvular heart disease, peripartum cardiomyopathy, systemic lupus erythematosus, high risk for HIV infection, cirrhosis, liver tumor, sickle cell disease, solid organ transplantation, and drug interactions with antiretrovirals used for prevention or treatment of HIV infection); and 3) inclusion of new contraceptive methods, including new doses or formulations of combined oral contraceptives, contraceptive patches, vaginal rings, progestin-only pills, levonorgestrel intrauterine devices, and vaginal pH modulator. The recommendations in this report are intended to serve as a source of evidence-based clinical practice guidance for health care providers. The goals of these recommendations are to remove unnecessary medical barriers to accessing and using contraception and to support the provision of person-centered contraceptive counseling and services in a noncoercive manner. Health care providers should always consider the individual clinical circumstances of each person seeking contraceptive services. This report is not intended to be a substitute for professional medical advice for individual patients; when needed, patients should seek advice from their health care providers about contraceptive use.
Cardiac Valve Prosthesis and Pregnancy: Challenges and Strategies.
Nomura M Arq Bras Cardiol. 2025; 122(1):e20240602.
PMID: 40052972 PMC: 11834729. DOI: 10.36660/abc.20240602.
Zhao X, Luo M, Tian Q Future Sci OA. 2025; 11(1):2459001.
PMID: 39920891 PMC: 11812333. DOI: 10.1080/20565623.2025.2459001.
Brenner E, Grewe M, Berenblum Tobi C, Bryant A, Dubinsky M, Zhang X Crohns Colitis 360. 2025; 7(1):otae078.
PMID: 39760126 PMC: 11700615. DOI: 10.1093/crocol/otae078.
Estrogen, progestin, and beyond: thrombotic risk and contraceptive choices.
Skeith L, Bates S Hematology Am Soc Hematol Educ Program. 2024; 2024(1):644-651.
PMID: 39644023 PMC: 11665608. DOI: 10.1182/hematology.2024000591.
Zia Y, Somerson E, Folse C, Alvarez A, Albergate Davis K, Comfort A Reprod Health. 2024; 21(1):171.
PMID: 39581967 PMC: 11587542. DOI: 10.1186/s12978-024-01908-9.